Molecular Test Assessments

Molecular Test Assessments are comprehensive health technology assessments of molecular tests across a range of conditions and applications. Each report provides a clear, objective view of the science behind a specific molecular test, the clinical evidence supporting the test, the manufacturer, an explanation of how the test is used in clinical practice, and appropriate patient selection criteria.

These reports include the Hayes Rating to indicate the overall strength and direction of the body of evidence for the molecular test. Molecular Test Assessments provide evidence-based support for the development of coverage policy, utilization management, and evidence-based clinical practices. Reports are reviewed annually up to 5 years post publication to determine if there is new literature or evidence that would impact a change in rating and warrant an updated report.

DecisionDx-UM (Castle Biosciences Inc.)

 

Uveal melanoma (UM) is the most common form of primary eye cancer. The incidence of UM in the United States is approximately 4.3 cases per million. UM is more common in older individuals, with incidence rates peaking at age 70, and is associated with characteristics such as fair skin and eye color. UM affects the iris, ciliary body, and choroid portions of the uveal tract, the mi…

VeriStrat

Non-small cell lung cancer (NSCLC) encompasses squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In the United States in 2015, it is estimated that NSCLC was diagnosed in more than 221,000 individuals and resulted in more than 158,000 deaths. More than 80% of lung cancer patients have NSCLC. The VeriStrat test relies on matrix-…